Osteotech’s MagniFuse
This article was originally published in The Gray Sheet
Executive Summary
Bone graft material will launch in mid-2009 into the estimated $1.2 billion U.S. market for bone graft substitutes, Osteotech says Nov. 7. The device recently received 510(k) clearance as a bone graft substitute and bone void filler for use in the spine, pelvis and extremities. The product combines allograft bone within a polymer mesh that provides targeted and contained delivery, and avoids issues with graft site migration or irrigation often seen with other bone graft substitutes, Osteotech says. The device allows Osteotech to go head-to-head with bone morphogenetic protein products, says Osteotech President-Domestic Robert Wynalek